Co-infections associated with human immunodeficiency virus type 1 in pregnant women from southern Brazil: high rate of intraepithelial cervical lesions

Tornatore, Michele; Gonçalves, Carla Vitola; Bianchi, Mônica Steigleder; Germano, Fabiana Nunes; Garcês, Alzira Xavier; Soares, Marcelo A.; Machado, Elizabeth S.; Martínez, Ana Maria Barral de

doi:10.1590/s0074-02762012000200009

Cited by 13 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… c Denotes prevalence (total) derived from samples of PLHIV pregnant women among the population group PLHIV (heterosexual and pregnant women) including: Cameroon (2) 9.3%, 14.6%; Cote D’Ivoire (1) 9.0%; Nigeria (1) 4.2%; South Africa (3) 6.2%, 3.4%, 2.1%; Malawi (1) 8.7%; Rwanda (1) 2.4%; Tanzania (1) 6.2%; Uganda (1) 4.9%; Brazil (5) 1.9%, 0.5%, 2.3%, 0.9%, 1.2%; USA (1) 2.9%; Canada (1) 5.6%; Haiti (1) 2.4%; France (2) 6.0%, 6.9%; the Netherlands (1) 4.9%, and Morocco (1). …”

Section: Resultsmentioning

confidence: 99%

Prevalence and burden of HBV co‐infection among people living with HIV: A global systematic review and meta‐analysis

Platt

French

McGowan

et al. 2019

Journal of Viral Hepatitis

105

View full text Add to dashboard Cite

Globally, in 2017 35 million people were living with HIV (PLHIV) and 257 million had chronic HBV infection (HBsAg positive). The extent of HIV‐HBsAg co‐infection is unknown. We undertook a systematic review to estimate the global burden of HBsAg co‐infection in PLHIV. We searched MEDLINE, Embase and other databases for published studies (2002‐2018) measuring prevalence of HBsAg among PLHIV. The review was registered with PROSPERO (#CRD42019123388). Populations were categorized by HIV‐exposure category. The global burden of co‐infection was estimated by applying regional co‐infection prevalence estimates to UNAIDS estimates of PLHIV. We conducted a meta‐analysis to estimate the odds of HBsAg among PLHIV compared to HIV‐negative individuals. We identified 506 estimates (475 studies) of HIV‐HBsAg co‐infection prevalence from 80/195 (41.0%) countries. Globally, the prevalence of HIV‐HBsAg co‐infection is 7.6% (IQR 5.6%‐12.1%) in PLHIV, or 2.7 million HIV‐HBsAg co‐infections (IQR 2.0‐4.2). The greatest burden (69% of cases; 1.9 million) is in sub‐Saharan Africa. Globally, there was little difference in prevalence of HIV‐HBsAg co‐infection by population group (approximately 6%‐7%), but it was slightly higher among people who inject drugs (11.8% IQR 6.0%‐16.9%). Odds of HBsAg infection were 1.4 times higher among PLHIV compared to HIV‐negative individuals. There is therefore, a high global burden of HIV‐HBsAg co‐infection, especially in sub‐Saharan Africa. Key prevention strategies include infant HBV vaccination, including a timely birth‐dose. Findings also highlight the importance of targeting PLHIV, especially high‐risk groups for testing, catch‐up HBV vaccination and other preventative interventions. The global scale‐up of antiretroviral therapy (ART) for PLHIV using a tenofovir‐based ART regimen provides an opportunity to simultaneously treat those with HBV co‐infection, and in pregnant women to also reduce mother‐to‐child transmission of HBV alongside HIV.

show abstract

Section: Resultsmentioning

confidence: 99%

Prevalence and burden of HBV co‐infection among people living with HIV: A global systematic review and meta‐analysis

Platt

French

McGowan

et al. 2019

Journal of Viral Hepatitis

105

View full text Add to dashboard Cite

show abstract

“…19,26 The administration of the HBV vaccine and HBV-specific immunoglobulin within 12 h of birth increases the efficacy of the prophylactic program from 72% (through routine vaccination alone) to 97%. 7,27 Therefore, routine screening of pregnant women remains important in countries where the vaccine is administered, as the diagnosis of HBV infection can help guide the healthcare team in administering immunoglobulin to the newborn.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of syphilis, human immunodeficiency virus, hepatitis B virus, and human T-lymphotropic virus infections and coinfections during prenatal screening in an urban Northeastern Brazilian population

Moura

Mello

Correia

2015

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Most of the studies, conducted in South and Southeast regions of Brazil, have reported HIV-HBV coinfection prevalence, ranging from 2.3% to 27.3%. [3][4][5][6][7] Furthermore, this is the first study reporting the HBV genotypes in HIV infected individuals in Central-West Region of Brazil.…”

Section: Introductionmentioning

confidence: 85%

Prevalence, risk factors and genotypes of hepatitis B infection among HIV-infected patients in the State of MS, Central Brazil

Freitas

Soares

Tanaka

et al. 2014

The Brazilian Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

Co-infections associated with human immunodeficiency virus type 1 in pregnant women from southern Brazil: high rate of intraepithelial cervical lesions

Cited by 13 publications

References 26 publications

Prevalence and burden of HBV co‐infection among people living with HIV: A global systematic review and meta‐analysis

Prevalence and burden of HBV co‐infection among people living with HIV: A global systematic review and meta‐analysis

Prevalence of syphilis, human immunodeficiency virus, hepatitis B virus, and human T-lymphotropic virus infections and coinfections during prenatal screening in an urban Northeastern Brazilian population

Prevalence, risk factors and genotypes of hepatitis B infection among HIV-infected patients in the State of MS, Central Brazil

Contact Info

Product

Resources

About